NEW YORK, June 11 /PRNewswire-FirstCall/ -- Dr. Joshua Schein, Chief Executive Officer of Lev Pharmaceuticals, Inc. (“Lev” or the “Company”) , will present at Needham & Co.'s Sixth Annual Biotechnology and Medical Technology Conference at The New York Palace Hotel in New York City, NY on Thursday, June 14, 2007.
The Lev Pharmaceuticals, Inc. presentation is scheduled to begin at 2:30 PM. It will be accessible via webcast by clicking on the link: http://www.wsw.com/webcast/needham18/levp.ob/.
The above link can be used for both the live and archived webcast. The webcast will automatically be archived on the date of the live event and will be available for 90 days.
For information about Needham & Co.'s Sixth Annual Biotechnology and Medical Technology Conference, please visit: http://www.needhamco.com or e-mail: conferences@needhamco.com.
ABOUT LEV PHARMACEUTICALS
Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. The Company recently announced successful Phase III Clinical CHANGE (C1-inhibitor in Hereditary Angioedema Nano filtration Generation evaluating Efficacy) Trial results of its lead product, C1-INH-nf (C1-INH nano- filtration), for the acute treatment of Hereditary Angioedema (HAE). In addition, Lev recently completed a registrational Phase III clinical trial for the prophylactic treatment of HAE. Based on the positive results of the CHANGE study, the Company intends to submit a Biologics License Application to the Food and Drug Administration in the second quarter of 2007. The Company is also evaluating the development of C1-INH for the treatment of acute myocardial infarction, or heart attack, and selective other diseases and disorders in which inflammation is known or believed to play an underlying role. Lev’s C1-INH has been granted orphan drug status for the treatment and prevention of HAE, potentially securing, upon approval, market exclusivity for seven years. The Company has also received fast track designation status from the FDA, which facilitates the development and expedites the review of drugs and biologics intended to treat serious or life threatening conditions and that demonstrate the potential to address unmet medical needs.
Patients and physicians interested in obtaining more information about Lev’s studies for hereditary angioedema should contact the Company directly at 212-682-3096, or visit the Company’s website at http://www.levpharma.com.
Legal notice to investors: Certain matters discussed in this news release are “forward-looking statements.” These forward-looking statements, which apply only on the date of this release, generally can be identified by the use of forward-looking terminology such as “may,” “will,” “expects,” “intends,” “estimates,” “anticipates,” “believes,” “continues” or words of similar import. Similarly, statements that describe Lev’s future plans, objectives or goals are also forward-looking statements, which generally involve known and unknown risks, uncertainties and other facts that may cause the actual results, performance or achievements of Lev to be materially different from those expressed or implied by such forward-looking statements. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the completion of clinical trials, the FDA review process and other governmental regulation, our ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies. These statements are based on our current beliefs and expectations as to such future outcomes and Lev disclaims any obligation to update the forward-looking statements made herein.
Lev Pharmaceuticals, Inc.
CONTACT: Jason Tuthill, Director of Investor Relations of LevPharmaceuticals, Inc., +1-212-850-9130, jtuthill@levpharma.com
Web site: http://www.levpharma.com/
